Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations.

European journal of nuclear medicine and molecular imaging - 1 Apr 2026

Daoud Tarek, Chen Jiansong, Wei Peng, Wong Franklin, Yap Timothy A, Lin Lilie L

Abstract excerpt

PURPOSE: Inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme with numerous roles in DNA damage response signaling, represent a class of anti-cancer drugs approved for treating solid tumors with defects in the DNA damage response. However, additional methods for identifying patients who would benefit from the use of PARP inhibitors are urgently needed. We evaluated a novel radiotracer, 18F-FluorThanatrace...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to Mutation

Share to Neoplasms

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Positron Emission Tomography Computed Tomography

Source

Open in PubMed Open full text

Identifiers

PMID: 41251745
DOI: 10.1007/s00259-025-07595-3
PMCID: PMC13013147

Genes

BRCA2
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations.PMID 41251745Read ↗

[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.Semantic proximity Read ↗

Molecular Imaging: PARP-1 and BeyondSemantic proximity Read ↗

[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancerSemantic proximity Read ↗

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and RadiotherapySemantic proximity Read ↗

A novel <sup>18</sup> F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1Semantic proximity Read ↗

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic ProbesSemantic proximity Read ↗

A PET imaging agent for evaluating PARP-1 expression in ovarian cancerSemantic proximity Read ↗

In vivo visualization of PARP inhibitor pharmacodynamicsSemantic proximity Read ↗

Molecular Imaging of PARPSemantic proximity Read ↗

Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib.Semantic proximity Read ↗

The evolving landscape of predictive biomarkers of response to PARP inhibitorsSemantic proximity Read ↗

Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.